Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Categories (click each to see list of all clinical trials associated with that category): Leukemia/MDS/MPD (ONC)
Current Status: Open
Phase: II (Cancer Control)
Principal Investigator: Haddadin, Michael
Contact Information:
Penny Hardiman, RN
402-559-4135
penny.hardiman@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT05554406?term=NCT05554406&rank=1#participation-criteria
Summary
1.1 Primary Objectives
a. To compare measurable residual disease (MRD) negative complete remission
(CR) rates between each of the experimental regimens and Cytarabine +
Daunorubicin (7+3).
1.2 Secondary Objective(s)
a. To estimate the frequency and severity of toxicities with each of the regimens.
b. To estimate complete remission (CR) rates, complete remission with incomplete
count recovery (CRi, with and without MRD) rates, event-free survival (EFS), time
to relapse, relapse-free survival (RFS), and overall survival (OS) with each of the
regimens.
c. To describe and compare MRD negative CR rates by genomic subgroups within
and across randomized arms.
1.3 Banking Objectives
a. To bank specimens for future correlative studies (refer to Section 15 of MYELOMATCH).